Company: NCEL
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026428
Chunk: 353

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: F-4/A
Chunk 353
---
 |           — |   |     |       |     |             |  (1,238,425 | ) |     | -R    |     |           |          — |
| Share premium                                                                         |     |               | 62,286,200 |     |                  |          — |     |             |           — |   |     |       |     |             | (62,286,200 | ) |     | -R    |     |           |          — |

193

Kadimastem Ltd. & NLS Pharmaceutics Ltd.
Unaudited Pro Forma Condensed Combined Balance Sheets — (Continued)

|                                                                                                                                                                                                        |     | June 30, 2024 |             |   |     |                  |             |   |     |             |            |   |     |       |     |             |             |   |     |       |     |           |             |   |
|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:----|:--------------|------------:|:--|:----|:-----------------|------------:|:--|:----|:------------|-----------:|:--|:----|:------|:----|:------------|------------:|:--|:----|:------|:----|:----------|------------:|:--|
|                                                                                                                                                                                                        |     | Kadimastem,   
 Ltd.          |             |   |     | NLS              
 Pharmaceuticals, 
 Inc.             |             |   |     | Pro Forma   
 Adjustments 
 NLS         |            |   |     | Notes |     | Pro Forma   
 Adjustments 
 Kadimastem  |             |   |     | Notes |     | Pro Forma 
 Combined  |             |   |
| Common shares, CHF 0.80 ($0.80) par value, 985,723 and 810,723 registered shares issued and outstanding at June 30, 2024 and December 31, 2023; Pro forma 34,256,529 shares CHF 0.03 ($0.03) par value |     |               |           — |   |     |                  |     808,555 |   |     |             |     72,334 |   |     | -B    |     |             |           — |   |     |       |     |           |   1,133,960 |   |
|                                                                                                                                                                                                        |     |               |             |